技术指标
指标
数值
方向
MACD(12,26,9)
0.004
中性
RSI(14)
31.846
中性
STOCH(KDJ)(9,3,3)
14.757
超卖
ATR(14)
0.097
低波动
CCI(14)
-114.283
卖出
Williams %R
93.548
超卖
TRIX(12,20)
-1.244
卖出
StochRSI(14)
33.633
卖出
搜索
GRI Bio Inc
GRI添加自选
1.390USD
-0.020-1.42%
收盘 07-31 16:00（美东）报价延迟15分钟
24.71K总市值
亏损市盈率 TTM
关键数据
1.420今开
1.465最高
23.77K成交量
亏损市盈率 TTM
亏损市盈率动
--股息TTM
133.71%换手率
1.410昨收
1.360最低
15.57K成交额
亏损市盈率静
0.00市净率
0.00%股息率 TTM
-141.84%ROA
80.36052周最高
0.91量比
-10.12M净利润
17.77K总股本
-3249.6573每股收益TTM
-1.18Beta
-185.67%ROE
1.97052周最低
7.45%振幅
--毛利率
24.71K总市值
-4.12回报/风险
5.97%风险率
TradingKey GRI Bio Inc股票评分
单位: USD 更新时间: 2026-07-30操作建议
GRI Bio Inc当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名137/384位。机构持股占比很高，近一月多位分析师给出公司评级为买入。最高目标价156.00。中期看，股价处于下降通道。近一个月，市场表现非常差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
GRI Bio Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
GRI Bio Inc亮点
亮点风险
GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. The Company’s therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The Company is also developing a pipeline of novel type II diverse NKT agonists for the treatment of systemic lupus erythematosus. Its product candidate portfolio also includes GRI-0803 and a proprietary library of more than 500 compounds. It is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) and multiple sclerosis (MS).
估值高估
公司最新PE估值-0.00，处于3年历史高位
机构加仓
最新机构持股10.85K股，环比增加32.67%
分析师目标
根据
2
位分析师
买入
评级
156.000
目标均价
+11042.86%
涨幅空间
GRI Bio Inc新闻
即将为您带来更多新闻，敬请期待。。。
收益预测
分析师评级
根据
2
位分析师
买入
评级
156.000
目标均价
+10512.24%
涨幅空间
强力买入
买入
持有
卖出
强力卖出
同行比较
496
总数
6
中位数
7
平均值
公司名称
评级分布
分析师数
GRI Bio Inc
GRI
2
百济神州
ONC
27
argenx SE
ARGX
26
艾昆纬
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
23
1
2
3
...
99
技术指标
移动平均线
指标
数值
方向
MA5
1.418
卖出
MA10
1.450
卖出
MA20
1.564
卖出
MA50
1.856
卖出
MA100
2.127
卖出
MA200
3.266
卖出
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
GRI Bio Inc简介
GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. The Company’s therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The Company is also developing a pipeline of novel type II diverse NKT agonists for the treatment of systemic lupus erythematosus. Its product candidate portfolio also includes GRI-0803 and a proprietary library of more than 500 compounds. It is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) and multiple sclerosis (MS).
公司代码GRI
公司GRI Bio Inc
CEOHertz (W. Marc)
网址https://www.gribio.com/
公司股东
相关品种
热门品种
常见问题
GRI Bio Inc(GRI)的当前股价是多少？
GRI Bio Inc(GRI)的当前股价是 1.39。
GRI Bio Inc的股票代码是什么？
GRI Bio Inc的股票代码是GRI。
GRI Bio Inc股票的52周最高点是多少？
GRI Bio Inc股票的52周最高点是80.36。
GRI Bio Inc股票的52周最低点是多少？
GRI Bio Inc股票的52周最低点是1.97。
GRI Bio Inc的市值是多少？
GRI Bio Inc的市值是24.71K。
现在GRI Bio Inc(GRI)的股票是买入、持有还是卖出？
根据分析师评级，GRI Bio Inc(GRI)的总体评级为买入，目标价格为156.00。
GRI Bio Inc(GRI)股票的每股收益（EPS TTM）是多少
GRI Bio Inc(GRI)股票的每股收益（EPS TTM）是-3410.36。